RYR2 and glioblastoma: Notably, all of the subclonal mutations in GBM (DNAH5, AHNAK, AHNAK2, and CD163L1, Figure 2(a)) and most of the subclonal mutations in LGG (PTEN, RYR2, NF1, and FLG, Figure 2(b)) showed significantly poor prognosis, suggesting that subclonal mutation preferred to be a risk factor.